• To determine if AMD3100, given with a G-CSF mobilizing regimen, is generally safe and well tolerated. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  
• To determine the percentage of patients who previously failed mobilization with conventional methods who are successfully mobilized by AMD3100 given with G-CSF. [ Time Frame: Maximum of 7 days from first dose to last ] [ Designated as safety issue: No ]
  

• To determine the times of PLT and PMN engraftment. [ Time Frame: from transplant to engraftment ] [ Designated as safety issue: No ]
  
• To evaluate the durability of engraftment after transplantation [ Time Frame: 3, 6 and 12 months post-transplant. ] [ Designated as safety issue: No ]
  
• To examine the pharmacokinetics of repeated doses of AMD3100 [ Time Frame: after each dose of AMD3100 ] [ Designated as safety issue: No ]
  
• To determine if non-Hodgkin's lymphoma tumor cells are mobilized after either G-CSF mobilization or AMD3100 administration. [ Time Frame: after G-CSF mobiliation period ] [ Designated as safety issue: Yes ]
  

This is a Phase 2, multicenter, prospective, observational, open-label study. Once 70 patients have enrolled, subsequent patients enrolled must have a diagnosis of lymphoma. Patients who would benefit from an autologous stem cell transplant, who have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests and who meet the inclusion/exclusion criteria are eligible to receive AMD3100 as outlined in this protocol. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 on the evening prior to each day of apheresis.

Patients will undergo mobilization with G-CSF (10 µg/kg) for 4 days. On Day 4, AMD3100 (240 µg/kg) will be administered in the evening prior to the first apheresis and each subsequent evening prior to apheresis thereafter, such that there is a 10 to 11 hour interval between dosing and the initiation of apheresis. Patients will continue to receive G-CSF on each day of apheresis. Patients will undergo a minimum of 2 and a maximum of 7 aphereses or until ≥2 x 10e6 CD34+ cells/kg are collected, whichever occurs first. In addition, the mobilization of NHL tumor cells and the pharmacokinetics of repeat doses of AMD3100 will be examined.

After the last apheresis has been completed, or after the patient has collected ≥2 x 10e6 CD34+ cells/kg, he/she will be treated with high-dose chemotherapy in preparation for transplantation. Patients will be transplanted with cells obtained from the G-CSF with AMD3100 mobilization regimen. In the event that the minimum number of ≥2 x 10e6 cells for transplantation are not obtained from the first mobilization with AMD3100, cells may be retained and pooled for transplantation with those from a second mobilization with AMD3100, at the investigator's discretion. If a second mobilization with AMD3100 is attempted, a minimum rest interval of one week should be allowed between the last apheresis of the first regimen and the first dose of G-CSF of the second. The number of CD34+ cells mobilized in the peripheral blood (PB),collected in the apheresis product, and the number of apheresis sessions performed will be measured. Success of the transplantation will be evaluated.

Inclusion Criteria:

• Age 18 to 78 years
• Eligible to undergo autologous transplantation
• Has failed previous collections or collection attempts with a mobilization regimen of G-CSF, chemotherapy and G-CSF or any other conventional therapy including cytokines, chemotherapy and cytokines or bone marrow harvest.
• ECOG performance status of 0 or 1
• ≥3 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study) NOTE: Although thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study, none are to be administered within 7 days prior to the first dose of G-CSF (see Exclusion Criteria).
• The patient has recovered from all acute toxic effects of prior chemotherapy
• WBC >2.5 x 10e9/l
• Absolute neutrophil count >1.5 x 10e9/l
• Platelet count >85 x 10e9/l
• Serum creatinine ≤1.5 mg/dl
• Creatinine clearance >60 ml/min
• SGOT, SGPT and total bilirubin <2x upper limit of normal
• Left ventricle ejection fraction >45% (by normal ECHO or MUGA scan)
• FEV1 >60% of predicted or DLCO ≥45% of predicted
• No active infection of hepatitis B or C
• Negative for HIV
• Signed informed consent
• Women of child-bearing potential agree to use an approved form of contraception

Exclusion Criteria:

• Once 70 patients have enrolled, patients with diagnoses other than lymphoma are not eligible (eg, AML CLL, or MM).
• A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications
• A residual acute medical condition resulting from prior chemotherapy
• Received thalidomide, dexamethasone, and/or Velcade™ within 7 days prior to the first dose of G-CSF
• Brain metastases or carcinomatous meningitis
• Acute infection
• Fever (temperature >38°C/100.4°F)
• Hypercalcaemia (>1 mg/dl above the ULN)
• Positive pregnancy test in female patients
• Lactating females
• Patients of child-bearing potential unwilling to implement adequate birth control
• Patients whose actual body weight exceeds 175% of their ideal body weight
• Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the Mobilization phase